Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:00 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1657–1680 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Cirrhosis
Interventions: OCR-002 IR Oral Tablet, OCR-002 Oral Solution, OCR-002 IV Solution; Drug
Lead sponsor: Ocera Therapeutics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Coronado, California

Conditions: Torticollis, Dystonia
Interventions: CBT; Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Skin Cancer
Interventions: Nevisense 3.0, Dermlite Cam, Skin biopsy, Barco Demetra; Device · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: ABBV-313, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Anaheim, California • Grayslake, Illinois

Conditions: Breast Cancer
Interventions: Fulvestrant, Debio 1347; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Hematological Disorders
Interventions: ORH-2014; Drug
Lead sponsor: Orsenix LLC; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: New York, New York • Nashville, Tennessee • Houston, Texas

Conditions: Myeloma
Interventions: Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up; Drug · Other
Lead sponsor: Robert Redner, MD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 22
States / cities: Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more

Conditions: Colorectal Neoplasms, Gastrointestinal Neoplasms
Interventions: JNJ-89402638, Bevacizumab, FOLFOX, FOLFIRI; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 6
States / cities: Tucson, Arizona • Aurora, Colorado • Sarasota, Florida + 3 more

Conditions: Postoperative Pain
Interventions: Placebo, EXPAREL 67 mg, EXPAREL 133 mg, EXPAREL 266 mg; Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Birmingham, Alabama • Mobile, Alabama • Sheffield, Alabama + 23 more

Conditions: COVID-19
Interventions: Remdesivir, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Apremilast, dornase alfa, Celecoxib, Famotidine, IC14, Aviptadil, narsoplimab, Cyproheptadine, Cyclosporine; Drug · Biological
Lead sponsor: QuantumLeap Healthcare Collaborative; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 36
States / cities: Birmingham, Alabama • Davis, California • Irvine, California + 30 more

Conditions: Familial Hypercholesterolemia - Heterozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 9
States / cities: San Francisco, California • Washington D.C., District of Columbia • Boca Raton, Florida + 4 more

Conditions: Multiple Myeloma
Interventions: Linvoseltamab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2035
U.S. locations: 13
States / cities: Los Angeles, California • Orange, California • Denver, Colorado + 9 more

Conditions: Substance Use Disorders, Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Interventions: Low Intensity, High Intensity; Other
Lead sponsor: Gavin Bart; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Boston, Massachusetts • Minneapolis, Minnesota • New York, New York + 1 more

Conditions: Renal Impairment
Interventions: RO7795081; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Miami Lakes, Florida • Orlando, Florida • St. Petersburg, Florida

Conditions: Kidney Transplantation
Interventions: coenzyme Q10, Watermelon diet, Usual Diet, Placebo; Dietary Supplement · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Literacy
Interventions: 10-week Reading Program; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 6 Years to 7 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Type 2 Diabetes Mellitus (T2DM), Obesity
Interventions: Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Anaheim, California • South Miami, Florida

Conditions: Solid Tumors
Interventions: OPB-111077; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Fall Injury, Fall Patients, Mobility Limitation
Interventions: FAST Program, Otago Exercise Program; Other
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: DLBCL, Neurotoxicity Syndromes
Interventions: Defibrotide; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Anaplastic Thyroid Cancer, Thyroid Cancer, Differentiated Thyroid Cancer
Interventions: MLN0128; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 3
States / cities: Newport Beach, California • Boston, Massachusetts • Ann Arbor, Michigan

Conditions: Glioma
Interventions: 18F-FMISO PET, 18F-FLT PET; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Glioblastoma Multiforme
Interventions: Amgen 386, Bevacizumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 6
States / cities: Los Angeles, California • Boston, Massachusetts • Worcester, Massachusetts + 2 more

Conditions: Pain, Postoperative, Fracture, Ankle, Pilon Fracture of Tibia, Foot Fracture
Interventions: Auricular acupuncture; Device
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 64 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

OCR002-SP103 - Oral Immediate Release Study

OnabotulinumtoxinA in the Management of Psychogenic Dystonia

SpotCheck: Comparison of Enhanced Telemedicine Versus In-person Evaluation for the Diagnosis of Skin Cancer

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

A Phase I, Two-part Study to Determine the Recommended Dose and Evaluate the Safety and Tolerability of a Novel Oral Arsenic Trioxide Formulation (ORH-2014) in Subjects With Advanced Hematological Disorders

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Femoral Nerve Block With Liposome Bupivacaine for Postsurgical Analgesia Following Total Knee Arthroplasty

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia

A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment

EXHIT ENTRE Implementation Trial of High Intensity Versus Low Intensity Strategy

A Study Investigating the Safety of RO7795081 and How the Body Processes RO7795081 in People With Normal or Decreased Kidney Functions

Watermelon/UBIQuinone Study

Enhancing Reading Skills in 1st Grade Children

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

A Phase 1, Open-label, Multiple Dose Escalation Trial to Determine Safety and Tolerability of Once Daily OPB-111077 in Subjects With Advanced Cancer

Minimizing Fall-Related Injury in Older Adults: a Motor Learning Approach

A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Tumor Hypoxia and Proliferation in Patients With High-Grade Glioma

Amgen 386 for Recurrent Glioblastoma

Auricular Acupuncture as Part of Multimodal Analgesia After Lower Leg Fracture